KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2023;37(4):160-164 / www.klinickafarmakologie.cz 164 KAZUISTIKY Chirurgická liečba gynekomastie vyvolanej bikalutamidom, prehľad vybraných liekov spôsobujúcich nežiaduce účinky – gynekomastiu LITERATÚRA 1. Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. The American journal of medicine. 1984;77(4):633-638. Available from: https://doi.org/10.1016/ 0002-9343(84)90353-x. 2. Nuttall FQ. Gynecomastia as a physical finding in normal men. The Journal of clinical endocrinology and metabolism. 1979;48(2):338-340. Available from: https://doi.org/10.1210/ jcem-48-2-338. 3. Ordaz DL, Thompson JK. Gynecomastia and psychological functioning: A review of the literature. Body Image. 2015;15:141-148. Available from: https://doi.org/10.1016/j.bodyim.2015.08.004. 4. Miklisova D, Verbat M, Sutakova E, et al. Surgical treatment of Bicalutamide-induced gynecomastia. In: PlastSurgeon.com [on-line]. 2023 May [cited 2023 August 06]. Available from: https://plastsurgeon.com/case-competition-overview/case-competition-2023/case-17-surgical-excision-of-bicalutamide-induced-gynecomastia/. 5. Fagerlund A, Cormio L, Palangi L, et al. Gynecomastia in Patients with Prostate Cancer: A Systematic Review. PloS one. 2015;10(8):e0136094. Available from: https://doi.org/10.1371/ journal.pone.0136094. 6. Di Lorenzo G, Autorino R. Bicalutamide-Induced Gynaecomastia: Do We Have the Answer? European Urology. 2007;52(1):5-8. Available from: https://doi.org/10.1016/j.eururo.2007.01.063. 7. Ritter JM, Robinson E, Fullerton J, et al. Rang & Dale‘s Pharmacology (9th ed.) [on-line]. Elsevier – OHCE; 2018. Available from: https://bookshelf.health.elsevier.com/ books/9780702074455. 8. Souhrn údajů O přípravku Bicaluplex – Sukl.cz. Státní ústav pro kontrolu léčiv. (n.d.-a). [on-line]. Available from: https:// prehledy.sukl.cz/prehledy/v1/dokumenty/16464. 9. Haynes BA, Mookadam F. Male gynecomastia. Mayo Clinic proceedings. 2009;84(8):672. Available from: https://doi. org/10.1016/S0025-6196(11)60515-6. 10. Jeunemaitre X, Kreft-Jais C, Chatellier G, et al. Long-term experience of spironolactone in essential hypertension. Kidney Int Suppl. 1988;26:S14-S17. Available from: https://pubmed.ncbi.nlm.nih.gov/3199684/. 11. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64-73. doi:10.1592/phco.29.1.64. 12. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057. doi:10.4065/80.8.1050. 13. Mendhekar DN, Andrade CR. Unilateral gynecomastia induced by risperidone in a geriatric male patient. Indian J Med Sci. 2005;59(8):361-362. 14. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003. 15. Mabini R, Wergowske G, Baker FM. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatr Serv Wash DC. 2000;51(8):983-985. doi:10.1176/ appi.ps.51.8.983. 16. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry. 1999;32(1):41. doi:10.1055/ s-2007-979187. 17. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61. doi:10.1097/00004714199902000-00011. 18. Shahi MK, Kar SK. Asymmetric, Tender Gynecomastia Induced by Olanzapine in a Young Male. Indian J Psychol Med. 2017;39(2):215-216. Available from: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC5385759/. 19. Aiman U, Haseeen MA, Rahman SZ. Gynecomastia: An ADR due to drug interaction. Indian journal of pharmacology. 2009;41(6):286-287. Available from: https://doi. org/10.4103/0253-7613.59929. 20. He B, Carleton B, Etminan M. Risk of Gynecomastia with Users of Proton Pump Inhibitors. Pharmacotherapy. 2019;39(5):614-618. Available from: https://doi.org/10.1002/phar.2245. 21. Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy. 2012;32(12):1123-1140. doi:10.1002/ phar.1138. 22. Wilt TJ, Macdonald R, Hagerty K, et al. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int. 2010;106(10):1444-1451. doi:10.1111/j.1464-410X.2010.09714.x. 23. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981;19(6): 1073-1074. doi:10.1128/AAC.19.6.1073. 24. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057. doi:10.4065/80.8.1050. 25. Klein JJ, Segal RL, Warner RRP. Galactorrhea Due to Imipramine. Available from: http://dx.doi.org/10.1056/ NEJM196409032711008. doi:10.1056/NEJM196409032711008. 26. Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. Br J Psychiatry J Ment Sci. 1985;147:87-88. doi:10.1192/bjp.147.1.87. 27. Arroyo H. Gynecomastia induced by a monoamine oxidase inhibitor. Presse Med. 1966;74(34):1764. 28. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry. 1993;150(8):1269-1270. doi:10.1176/ajp. 150.8.1269a. 29. Hall MJ. Breast tenderness and enlargement induced by sertraline. Am J Psychiatry. 1994;151(9):1395-1396. doi:10.1176/ ajp.151.9.1395b. 30. Karakurt F, Kargili A, Uz B, et al. Venlafaxine-induced gynecomastia in a young patient: a case report. Clin Neuropharmacol. 2009;32(1):51-52. doi:10.1097/WNF.0B013E3181679126. 31. Weydt P, Schönfeldt-Lecuona CJ, Gahr M, et al. Hypogonadism and gynecomastia with duloxetine. Pharmacopsychiatry. 2011;44(2):77. doi:10.1055/s-0031-1271684. 32. Damsa C, Bumb A, Bianchi-Demicheli F, et al. “Dopamine-dependent” side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry. 2004;65(8):10641068. doi:10.4088/jcp.v65n0806. 33. Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol. 2015;71(5):569-578. doi:10.1007/s00228-015-1835-x. 34. European database of suspected adverse drug reaction reports [on-line]. Available from: http://www.adrreports.eu/ en/search_subst.html#. [cited 2023 October 15]. 35. Swerdloff RS. MACP Gynecomastia: Etiology, Diagnosis, and Treatment [on-line]. Endotext; 2023. Available from: .https://www.ncbi.nlm.nih.gov/books/NBK279105/#:~:text=There%20are%203%20classes%20of,such%20as%20letrozole%20 and%20anastrozole. 36. Mett TR, Pfeiler PP. Surgical treatment of gynaecomastia: a standard of care in plastic surgery. European Journal of Plastic Surgery. 2020;43:389-398. Available from: https://link. springer.com/article/10.1007/s00238-019-01617-8#ref-CR1. 37. More Men Undergo Plastic Surgery as the Daddy-Do-Over Trend Rises in Popularity. American Society of Plastic Surgeons, 2018 National Clearinghouse of Plastic Surgery Available from: https://www.plasticsurgery.org/news/press-releases/more-men-undergo-plastic-surgery-as-the-daddy- -do-over-trend-rises-in-popularity. 38. He W, Wei W. A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia. BMC Endocrine Disorders. 2023;Article number: 62. Available from: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/ s12902-023-01310-9#:~:text=In%20one%20cohort%20study%2C%20TAM,than%2012%20months%20%5B12%5D. 39. Fricke A, Lehner GM, Stark GB, et al. Long-Term Follow- -up of Recurrence and Patient Satisfaction After Surgical Treatment of Gynecomastia. Aesthetic plastic surgery. 2017;41(3):491-498. Available from: https://doi.org/10.1007/ s00266-017-0827-x).
RkJQdWJsaXNoZXIy NDA4Mjc=